Literature DB >> 306420

Metabolism of immunoglobulin A, lymphocyte function, and histocompatibility antigens in patients on anticonvulsants.

R A Shakir, P O Behan, H Dick, D G Lambie.   

Abstract

Low serum IgA levels were found in patients taking phenytoin, together with evidence of depressed T cell function. There was no correlation between the dose or the serum level. A correlation was found, however, with HL-A status, patients with a low IgA showing increased frequency of HL-A2. It is suggested that epileptic patients with HL-A2 status are likely to develop IgA deficiency when given phenytoin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 306420      PMCID: PMC493022          DOI: 10.1136/jnnp.41.4.307

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  17 in total

1.  Hypogammaglobulinemia, primary and secondary: immunoglobulin levels (gamma-G, gamma-A, gamma-M) in one hundred and twenty-five patients.

Authors:  H N Claman; T F Hartley; D Merrill
Journal:  J Allergy       Date:  1966-10

2.  Immune imbalance in dysgammaglobulinaemia type IV.

Authors:  J R Hobbs
Journal:  Lancet       Date:  1968-01-20       Impact factor: 79.321

3.  Is phenytoin carcinogenic?

Authors:  G R Kruger; D Harris
Journal:  Lancet       Date:  1972-02-05       Impact factor: 79.321

4.  Abnormalities in IgA-containing mononuclear cells in the gastric lesion of pernicious anaemia.

Authors:  R J Odgers; A G Wangel
Journal:  Lancet       Date:  1968-10-19       Impact factor: 79.321

5.  Human immunoglobulin A.

Authors:  T B Tomasi
Journal:  N Engl J Med       Date:  1968-12-12       Impact factor: 91.245

6.  Letter: Impaired cell-mediated immunity in human brain tumours.

Authors:  D G Thomas; C B Lannigan; P O Behan
Journal:  Lancet       Date:  1975-06-21       Impact factor: 79.321

7.  Inhibition of transformation of normal lymphocytes by plasma factor from patients with Hodgkin's disease and cancer.

Authors:  P G Scheurlen; W Schneider; A Pappas
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

8.  IgA deficiency, epilepsy, and hydantoin medication.

Authors:  A Fontana; P J Grob; R Sauter; H Joller
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

9.  Immunological abnormalities in patients who had the oculomucocutaneous syndrome associated with practolol therapy.

Authors:  P O Behan; W M Behan; F J Zacharias; J T Nicholls
Journal:  Lancet       Date:  1976-11-06       Impact factor: 79.321

10.  Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin).

Authors:  T C Sorrell; I J Forbes; F R Burness; R H Rischbieth
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

View more
  7 in total

Review 1.  Immunoglobulins in epilepsy.

Authors:  J A Aarli
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Serum immunoglobulins in epileptic patients on anticonvulsant monotherapy.

Authors:  R A Kenny; B O'Neill; N Callaghan
Journal:  Ir J Med Sci       Date:  1982-01       Impact factor: 1.568

3.  Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins.

Authors:  K van Rijckevorsel-Harmant; M Delire; M Rucquoy-Ponsar
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

Review 4.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

5.  Immunological study of IgA deficiency during anticonvulsant therapy in epileptic patients.

Authors:  H Matsuoka; J Okada; T Takahashi; M Matsuoka; C Sato; S Torii
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

6.  The reversibility of phenytoin-induced IgA deficiency.

Authors:  N E Gilhus; J A Aarli
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

7.  Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A.

Authors:  A G Rolink; S T Pals; E Gleichmann
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.